Gene therapy injection aims to slow vision loss from dry AMD

NCT ID NCT06765980

Recruiting now Disease control Sponsor: Kriya Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tests a new gene therapy (VV-14295) given as an injection into the eye for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow the growth of these spots. About 62 adults aged 55 to 80 will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kriya Clinical Study Site
RECRUITING

Ottawa, Ontario, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••
Kriya Clinical Study Site
RECRUITING

Tel Aviv, Israel

Contact Phone: •••-•••-•••• Email: •••••@•••••
Kriya Clinical Study Site
RECRUITING

Christchurch, New Zealand

Conditions

Explore the condition pages connected to this study.

GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION